Chronic graft-versus-host disease (cGVHD) continues to be a major complication after
allogeneic hematopoietic cell transplantation, significantly affecting patients' quality of life. A …

Graft-versus-host disease (GVHD) represents a major complication after allogeneic
hematopoietic stem cell transplantation [1]. Chronic GVHD (cGVHD) is a significant cause of …

Background Graft-versus-host disease (GVHD) is a main complication following allogeneic
hematopoietic stem cell transplantation and is a leading cause of non-relapse-related death …

Graft-versus-host disease is the main cause of morbidity and mortality after allogeneic
hematopoietic stem cell transplantation. First-line treatment is based on the use of high …

Importance Ruxolitinib, a selective inhibitor of the Janus kinases 1/2 signaling pathway, has
shown a significant response in steroid-refractory chronic graft-vs-host disease (SR …

Background Chronic graft-versus-host disease (GVHD), a major complication of allogeneic
stem-cell transplantation, becomes glucocorticoid-refractory or glucocorticoid-dependent in …

Background Hematopoietic stem cell transplantation (HSCT) for haematological disorders.
Graft-versus-host disease (GVHD), a cause of morbidity and mortality is treated with …

Abstract On September 22, 2021, the Food and Drug Administration approved ruxolitinib for
the treatment of chronic graft-versus-host disease (cGVHD) after the failure of one or two …

Corticosteroid-refractory graft-versus-host disease (SR-GVHD) remains a significant source
of morbidity after allogeneic hematopoietic cell transplantation. No standard therapy exists in …

Abstract Background Graft-versus-Host Disease (GvHD) causes significant morbidity and
mortality in patients after allogeneic stem cell transplantation. Donor T-cells cause …